FIRST MIRODERM® TREATMENT IN THE MIROMATRIX HARD-TO-HEAL DIABETIC FOOT ULCER STUDY

Miromatrix, has announced that on August 4th the first subject enrolled into their multi-center Hard-to-Heal Diabetic Foot Ulcer study was treated with MIRODERM Biologic Wound Matrix by Dr. Payam Rafat of A Step Ahead Foot Care in New York.  Dr. M. Mason Macenski, Head of Clinical Affairs at Miromatrix, said, “I am pleased to initiate this trial and have the opportunity to further demonstrate the healing potential of this unique wound care matrix.”

A pilot series by Study Principal Investigator Dr. Robert Fridman of Foot Associates of New York, demonstrated that MIRODERM had substantially improved the healing of recalcitrant diabetic foot ulcers that previously failed other advanced wound therapies. In the pilot study MIRODERM closed 50% of the subjects’ hard-to-heal wounds within 12 weeks. This is notable in that the subjects’ wounds had been open for an average of more than 2 years and had received a median of 4 treatments with other advanced biologic products.  This motivated Miromatrix to initiate a larger multi-center trial. “It is important to treat and rapidly close diabetic foot ulcers. persistent wounds are predictive of poor clinical outcomes, including infection and possible amputation,” says Dr. Fridman. “The pilot study results showed that MIRODERM was able to heal challenging, long-standing wounds that have failed other advanced therapies and biologics. I am excited to have the opportunity to further evaluate MIRODERM in a larger, multi-centered clinical trial.”

MIRODERM Biologic Wound Matrix is the first-and-only wound matrix derived from porcine liver.  MIRODERM is manufactured using Miromatrix’s patented Perfusion Decellularization technology allowing the wound matrix to retain the intact extracellular matrix of the original biologic material including all vascular channels. MIRODERM is available in a variety of sizes both solid and fenestrated and is cleared for the management of wounds including but not limited to pressure ulcers, venous ulcers, chronic vascular ulcers and diabetic ulcers.  MIRODERM received an innovative technology contract from Vizient and was awarded a federal supply schedule contract for government sales.


About Miromatrix

Miromatrix, is a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products such as MIROMESH® and MIRODERM® for soft tissue reinforcement and advanced wound care.  Miromatrix’ perfusion decellularization/recellularization technology is protected by a series of issued patents and pending patent applications in all major markets around the world. In addition to MIROMESH and MIRODERM, internal development programs at Miromatrix focus primarily on creating fully implantable human organs including livers, kidneys and heart products, with collaborators including The Mayo Clinic, Texas Heart Institute and Mount Sinai Hospital, and aim at eliminating the organ transplant waiting list. 

Jeff Ross, Ph.D. CEO
(952) 942-6000
jross@miromatrix.com

 

Doris Taylor Rejoins Miromatrix As Scientific Advisor

Miromatrix is excited to announce the appointment of Doris A. Taylor, Ph.D., FACC, FAHA as a key scientific advisor. Dr. Taylor's groundbreaking research on perfusion decellularization and recellularization, which was published in Nature Medicine in 2008, is the basis of Miromatrix' patented technology.

"I am extremely pleased to rejoin Miromatrix in a consulting role,” says Dr. Taylor. “I founded Miromatrix in 2008 to apply the technology I helped pioneer. Since leaving the company, I followed its progress and watched it develop a new industry standard for hernia and advanced wound care. I believe the company’s new leadership combined with my intimate knowledge of this leading-edge technology will help Miromatrix realize its goal of bringing whole organs to patients worldwide. It's an exciting time for the company and for me.”

“We are extremely delighted to have Dr. Taylor rejoin Miromatrix and be a part of our talented team as we continue on our mission to end the organ transplant waiting list,” says Jeff Ross, Ph.D., CEO of Miromatrix. “Dr. Taylor brings a wealth of scientific and regulatory knowledge that will continue to help us accelerate our goals to create lifesaving organs,” Dr. Ross adds.

Dr. Taylor is the Director, Regenerative Medicine Research and Director of the Center for Cell and Organ Biotechnology at the Texas Heart Institute in Houston. She holds faculty appointments at both Texas A&M and Rice University and is a Fellow of the American College of Cardiology; American Heart Association Basic

Science Council and Council on Functional Genomics and Translational Biology, among others.  She has published extensively, authoring or co-authoring more than 130 scientific publications. She has been recognized for breakthrough research related to cell therapy, stem cell biology, and tissue engineering based therapies.  In addition to her research director responsibilities at THI, she co-directs the Cardiovascular Cell Therapy Research Network (CCTRN) Biorepository and leads a cell and cytokine profiling core lab that serves multiple NIH, National Heart Lung and Blood Institute (NHLBI) networks, medical centers, and research foundations in the U.S. and Canada.

About Miromatrix
Miromatrix Medical Inc., is a Minnesota-based biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products such as MIROMESH® and MIRODERM® for soft tissue reinforcement and advanced wound care, respectively.  Miromatrix’ perfusion decellularization/recellularization technology is protected by a series of issued patents and pending patent applications in all major markets around the world. In addition to MIROMESH and MIRODERM, internal development programs at Miromatrix focus primarily on creating fully implantable human organs including livers, kidneys and heart products, with collaborators including The Mayo Clinic, Texas Heart Institute and Mount Sinai Hospital, and aim at eliminating the organ transplant waiting list.  For more information visit www.miromatrix.com

Contact:
Jeff Ross, Ph.D.
(952) 942-6000
jross@miromatrix.com

August 7, 2017

Star Tribune: Miromatrix has high hopes for its bioengineered liver

The Star Tribune has published a piece about about Miromatrix.  The article highlights our progress towards creating the world's first bioengineered human liver.  

ows_150187625992511.jpg

 

"It may sound like science fiction, but the first attempt at this will take place before the year is out: A pig at the Mayo Clinic will have its liver removed, and a new liver “recellularized” with human and pig cells implanted in its place, to test whether a Miromatrix bioengineered liver can keep the pig alive for at least two days. Results of the experiment should be in by this time next year, and that may clear the way for the first human implant around 2020."

Click to read the whole article.

The Atlantic Includes Miromatrix in an Article

The Atlantic has featured Miromatrix in an article about how large pork businesses are creating new company units that will work with medical organizations interested in using pig tissues for medical devices and whole organ therapies.

The article highlights Miromatrix’ technology, our wound matrix and the development of transplantable organs based on our patented technology.  As the promise of fully biologic organs grows nearer we are excited to see porcine industry leaders, such as Smithfield Foods and Johnsonville, create entire biologic divisions to address the growing need for high-quality organ procurement for the medical market.  

Keeping the structure of the protein scaffold is important, which is why the company has special partnerships with local farms and slaughterhouses. “We make sure it doesn’t have any nicks and cuts it (sic), which takes a little bit of training,” says CEO Jeff Ross. He says the company is aiming to achieve the first human implant sometime in 2020 or 2021.

Click to read the article.

 

MIRODERM® Awarded Federal Supply Schedule Contract for Government Sales

Miromatrix Medical Inc., a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement and advanced wound care, announced today that they have been awarded a Federal Supply Schedule (FSS) contract to sell their product, MIRODERM® in all government facilities (e.g. VA Hospitals, DOD, etc.).  The MIRODERM family of products are acellular wound matrices derived from porcine liver and are intended for the management of wounds including: partial and full thickness wounds; venous and diabetic ulcers; surgical and trauma wounds, among others.  The earning of this contract adds MIRODERM to the existing contract that Miromatrix was awarded on December 1, 2016 for MIROMESH® (Contract Number V797D-70029). 

“With an FSS contract in place, we are excited to bring MIRODERM, our next-generation biologic wound matrix into the VA network of hospitals,” explained Jeff Ross, Ph.D., Chief Executive Officer of Miromatrix Medical.  “We are proud to be able to help the many veterans who serve our country.”

About Miromatrix:
Miromatrix Medical Inc. is a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products such as MIROMESH® and MIRODERM® for soft tissue reinforcement and advanced wound care.  Miromatrix’ perfusion decellularization/recellularization technology is protected by a series of issued patents and pending patent applications in all major markets around the world. In addition to MIROMESH and MIRODERM, internal development programs at Miromatrix focus primarily on creating fully implantable human organs including livers, kidneys and heart products with collaborators including The Mayo Clinic, Texas Heart Institute and Mount Sinai Hospital, and aim at eliminating the organ transplant waiting list.

 

Paul Buckman, John Erb, and Mark Wagner join Miromatrix' Board of Directors

We are delighted to announce that Paul Buckman, John Erb, and Mark Wagner have joined the Miromatrix Board of Directors! 

Collectively they bring over a 100 years of leadership experience in successfully developing and commercializing medical devices and medical technologies.  The willingness of these professionals to serve on the Board demonstrates their excitement about the remarkable potential of Miromatrix devices and technology to save lives and transform medicine.  It also highlights the Company’s compelling combination of a robust patent portfolio matched with exceptionally talented and dedicated people.  We are very excited about Mr. Buckman, Mr. Erb and Mr. Wagner joining the Board. 

Click the link to read the full press release.

Miromatrix Medical Receives Innovative Technology Contract from Vizient, Inc. for MIROMESH® and MIRODERM® Products

Miromatrix Medical is honored to announce that it has been awarded a Vizient Innovative Technology contract.  Vizient is "the largest member-owned health care company in the country and is dedicated to leading health care innovation, creating knowledge and fostering collaboration to help our members thrive." 

Click to read the full press release and watch the video below.

"Digital Trends" Published an Article About Miromatrix

Digital Trends, a publication focused on understanding how new technology effects our lives, published an article about Miromatrix.

"Our goal is nothing short of eliminating the organ transplant waiting list and saving the lives of the thousands of people who die each year waiting for an organ replacement."  

Click to read the article published by Digital Trends.

"Futurism" Published a Video about Miromatrix' Tech

Futurism is a publication that covers the breakthrough technologies and scientific discoveries that will shape humanity’s future.

Futurism posted a short video about Miromatrix’ patented organ technology and how they hope to save lives with it.  

View the video here or click here.   

Vice's "Motherboard" Covers Miromatrix

Motherboard is a publication that seeks to uncover the tech and science stories that define what's coming next.

"Reprogramming Organs Could Be the Future of Transplants"

Motherboard wrote a small article about Miromatrix' goal of eliminating the organ transplant waiting list.

Click on the link to read the article.  

CMS Grants MIRODERM® Biologic Wound Matrix with HCPCS Code Q-4175

The U.S. Centers for Medicare and Medicaid Services (CMS) has granted a HCPCS code (healthcare common procedure coding system) for MIRODERM® Biologic Wound Matrix, a non-crosslinked acellular wound matrices derived from porcine liver and indicated for the management of wounds including: partial and full thickness wounds; venous and diabetic ulcers; surgical and trauma wounds among others.  A HCPCS code is a required for reimbursement in the CMS and other health insurance program systems.

Miromatrix Medical Inc is a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement and advanced wound care.

NSF Highlights Miromatrix at the 2016 BIO International Convention

The National Science Foundation caught up with us at the 2016 BIO International Convention and highlighted our tech.
 
"Dominique Seetapun, Ph.D., Miromatrix’ senior project development scientist, says the new technique improves upon existing technologies, which largely immerse organs in detergents that also degrade organ scaffolds, and complicate the growth of new cells into functional tissues and organs. Instead of submerging organs entirely in detergent, Miromatrix instead pumps the decellularization solution through the blood vessels, removing cells in less time and avoiding degradation of the scaffold, she says. The organs then can be recellularized and transplanted using current organ transplantation techniques."

Click on the link to read the article or watch the video.  

Miromatrix Awarded Federal Supply Schedule Contract for Government Sales

Miromatrix Medical Inc., a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement and advanced wound care, announced today that they have been awarded a Federal Supply Schedule (FSS) contract to sell their product, MIROMESH® in all government facilities (e.g. VA Hospitals, DOD, etc.).  The earning of this contract further accentuates the innovative nature of MIROMESH, as it is the only highly vascularized porcine liver-derived biologic soft tissue reinforcement mesh in the world.  Pending review, MIRODERM®, Miromatrix’ porcine liver-derived biologic wound matrix is expected to be added to the contract in Q2 ’17.

“Eliminating the Organ Transplant Waiting List - The Future with Perfusion Decellularized Organs” In the Journal SURGERY

Miromatrix is proud to announce the recent publication of “Eliminating the Organ Transplant Waiting List - The Future with Perfusion Decellularized Organs” authored by Miromatrix’ Dominique Seetapun, Ph.D. and Jeff Ross, Ph.D. in the premier peer-reviewed journal SURGERY.  This publication highlights the ability of Miromatrix’ patented technology to address the chronic need for transplantable organs.

Perfusion decellularization is a method that utilizes the native vasculature, ducts or cavities of any solid organ to decellularize an organ and leave behind an extracellular matrix (ECM) scaffold with the native architecture, vasculature and biochemical markers intact. It has advanced tissue engineering from thin constructs to the engineering of whole organs.  In 2014, 20 patients died every day in the U.S. while waiting for an organ on the organ transplant waiting list. Patients who receive organ transplants are subject to the possibility of rejection and life-long immunosuppression. Perfusion decellularized organs have the potential to provide an ideal scaffold for recellularization and development of whole functional non-immunogenic transplantable organs. This review provides an overview of perfusion decellularization, progress in the field of whole bioengineered organs as well as potential future therapies that can be developed using perfusion decellularized scaffolds.

Click to view or download the peer-reviewed article published in the journal SURGERY.

Miromatrix on the Cover of Twin Cities Business Magazine

Miromatrix was honored to be on the front page of November 2016's Twin Cities Business Magazine.  

Dale Kurschner (Editor in Chief) writes "[...] Miromatrix will gain market share, and eventual market dominance, in the areas where it’s focusing its efforts because of its proprietary technology: It is the only company in the world that can run fluids through an organ’s own vascular structure to flush out all of its cells, and then reverse the process with a patient’s cells before transplanting part or all of the organ into his or her body. And the process does it so well, the organ retains everything needed for it to be infused with cells and brought back to life. No one else has perfected this."  

Click the link to read the article.  

MIROMESH Reaches Milestone of 1,000th Unit Shipped; MIRODERM Surpasses 500

Miromatrix Medical Inc., a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement and advanced wound care, announces that MIROMESH®, the only liver-derived biologic mesh indicated for soft tissue reinforcement, has surpassed 1,000 units shipped.  MIROMESH was launched in September 2014 and was created using Miromatrix’ proprietary perfusion decellularization technology.

Also this month, the combined shipments of MIRODERM®, MIRODERM® Fenestrated, and MIRODERM® Fenestrated Plus surpassed 500 units shipped.  The MIRODERM products are non-crosslinked acellular wound matrices derived from porcine liver and are intended for the management of wounds including: partial and full thickness wounds; venous and diabetic ulcers; surgical and trauma wounds among others.